References
1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A.
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
DOI:10.3322/caac.21262.
2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J
Clin. 2018;68:7-30. DOI:10.3322/caac.21442.
3 Darai E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel
lymph node biopsy in gynaecological cancers: the importance of
micrometastases in cervical cancer. SURG ONCOL. 2008;17:227-35.
DOI:10.1016/j.suronc.2008.04.002.
4 Niikura H, Okamoto S, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S,
et al. Prospective Study of Sentinel Lymph Node Biopsy Without Further
Pelvic Lymphadenectomy in Patients With Sentinel Lymph Node-Negative
Cervical Cancer. INT J GYNECOL CANCER. 2012;22:1244-50.
DOI:10.1097/IGC.0b013e318263f06a.
5 Cabanas RM. An approach for the treatment of penile carcinoma.
CANCER-AM CANCER SOC. 1977;39:456-66.
6 Tax C, Rovers MM, de Graaf C, Zusterzeel PL, Bekkers RL. The sentinel
node procedure in early-stage cervical cancer, taking the next step; a
diagnostic review. GYNECOL ONCOL. 2015;139:559-67.
DOI:10.1016/j.ygyno.2015.09.076.
7 NCCN Cervical cancer guidelines. Version II.2018; Available from.
https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf;
NCCN.org. (2018.11.10).
8 Chambers LM, Vargas R, Michener CM. Sentinel lymph node mapping in
endometrial and cervical cancer: a survey of practices and attitudes in
gynecologic oncologists. J GYNECOL ONCOL. 2019;30.
DOI:10.3802/jgo.2019.30.e35.
9 Abu-Rustum NR, Khoury-Collado F, Gemignani ML. Techniques of sentinel
lymph node identification for early-stage cervical and uterine cancer.
GYNECOL ONCOL. 2008;111: S44-S50.
DOI:https://doi.org/10.1016/j.ygyno.2008.07.027.
10 Di Guilmi J, Darin MC, Toscano M, Maya G. Laparoscopic Sentinel Lymph
Node Mapping with Indocyanine Green Using the iSpies Platform: Initial
Experience Argentina. J MINIM INVAS GYN. 2018;25:378-9.
DOI:https://doi.org/10.1016/j.jmig.2017.09.004.
11 Bricou A, Barranger E, Uzan S, Darai E. Anaphylactic shock during the
sentinel lymph node procedure for cervical cancer. GYNECOL ONCOL.
2009;114:375-6. DOI:https://doi.org/10.1016/j.ygyno.2009.04.027.
12 Sun SP, Zhang Y, Cui ZQ, Chen Q, Zhang W, Zhou CX, et al. Clinical
application of carbon nanoparticle lymph node tracer in the VI region
lymph node dissection of differentiated thyroid cancer. GENET MOL RES.
2014;13:3432-7. DOI:10.4238/2014.April.30.4.
13 Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, Chi
DS, et al. Improving sentinel lymph node detection rates in endometrial
cancer: How many cases are needed? GYNECOL ONCOL. 2009;115:453-5.
DOI:https://doi.org/10.1016/j.ygyno.2009.08.026.
14 Cibula D, Zikan M, Slama J, Fischerova D, Kocian R, Germanova A, et
al. Risk of micrometastases in non-sentinel pelvic lymph nodes in
cervical cancer. GYNECOL ONCOL. 2016;143:83-6.
DOI:10.1016/j.ygyno.2016.07.101.
15 Tanaka T, Sasaki S, Tsuchihashi H, Terai Y, Yamamoto K, Yamada T, et
al. Which is better for predicting pelvic lymph node metastases in
patients with cervical cancer: Fluorodeoxyglucose-positron emission
tomography/computed tomography or a sentinel node biopsy? A
retrospective observational study. Medicine (Baltimore). 2018;97:e0410.
DOI:10.1097/md.0000000000010410.
16 Dundr P, Cibula D, Nemejcova K, Ticha I, Bartu M, Jaksa R. Pathologic
Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer. Arch
Pathol Lab Med. 2019. doi:10.5858/arpa.2019-0249-RA.
17 Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, et al.
Prognostic outcome and complications of sentinel lymph node navigation
surgery for early-stage cervical cancer. INT J CLIN ONCOL.
2018;23:1167-72. DOI:10.1007/s10147-018-1327-y.
18 Lennox GK, Covens A. Can sentinel lymph node biopsy replace pelvic
lymphadenectomy for early cervical cancer? GYNECOL ONCOL.
2017;144:16-20. DOI:10.1016/j.ygyno.2016.08.337.
19 Yang SX, Wei WS, Jiang QH, Zhou YF, Qu W, Tu JH, et al. Analysis of
246 sentinel lymph node biopsies of patients with clinical primary
breast cancer by application of carbon nanoparticle suspension. J Obstet
Gynaecol Res. 2018;44:1150-7. DOI:10.1111/jog.13635.
20 Li Z, Ao S, Bu Z, Wu A, Wu X, Shan F, et al. Clinical study of
harvesting lymph nodes with carbon nanoparticle suspension in advanced
gastric cancer: a prospective randomized trial. World J Surg Oncol.
2016;14:88.
21 Zhao WJ, Luo H, Zhou YM, Gou ZH, Wang B, Zhu JQ. Preoperative
ultrasound-guided carbon nanoparticle suspension localization for
metastatic lymph nodes in papillary thyroid carcinoma during
reoperation: a retrospective cohort study. Medicine (Baltimore).
2017;96:e6285.
22 Lu Y, Wei JY, Yao DS, Pan ZM, Yao Y. Application of carbon
nanoparticles in laparoscopic sentinel lymph node detection in patients
with early-stage cervical cancer. PLOS ONE. 2017;12:e0183834.
DOI:10.1371/journal.pone.0183834.
23 Altgassen C, Hertel H, Brandstaedt A, Koehler C, Duerst M, Schneider
A. Multicenter validation study of the sentinel lymph node concept in
cervical cancer: AGO study group. J CLIN ONCOL. 2008;26:2943-51.
DOI:10.1200/jco.2007.13.8933.
24 Rocha A, Maria Dominguez A, Lecuru F, Bourdel N. Indocyanine green
and infrared fluorescence in detection of sentinel lymph nodes in
endometrial and cervical cancer staging - a systematic review. Eur J
Obstet Gynecol Reprod Biol. 2016;206:213-9.
DOI:10.1016/j.ejogrb.2016.09.027
25 Di Guilmi J, Darin MC, Toscano M, Maya G. Laparoscopic Sentinel Lymph
Node Mapping with Indocyanine Green Using the iSpies Platform: Initial
Experience Argentina. J MINIM INVAS GYN. 2018;25:378-9.
DOI:https://doi.org/10.1016/j.jmig.2017.09.004.
26 Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE. Adverse
reactions to patent blue V dye - The NEW START and ALMANAC experience.
Eur J Surg Oncol. 2010;36:399-403. DOI:10.1016/j.ejso.2009.10.007.
27 Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of
methylene blue dye for lymphatic mapping in breast cancer. AM J SURG.
2008;196:228-33. DOI:10.1016/j.amjsurg.2007.08.060.
28 Ouldamer L, Marret H, Acker O, Barillot I, Body G. Unusual
localizations of sentinel lymph nodes in early-stage cervical cancer: A
review. Surg Oncol. 2012;21: E153-E7. DOI:10.1016/j.suronc.2012.04.003.
29 Lukas R, Helena R, Jiri HM, Martin H, Petr S. Current status of
sentinel lymph node mapping in the management of cervical cancer. Expert
Rev Anticancer Ther. 2013;13:861-70. DOI:10.1586/14737140.2013.811147.
30 Daraï E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel
lymph node biopsy in gynaecological cancers: The importance of
micrometastases in cervical cancer. Surgical Oncology. 2008;17:227-35.
DOI:https://doi.org/10.1016/j.suronc.2008.04.002.
31 Cibula, D., Oonk, M. H. & Abu-Rustum, N. R. Sentinel lymph node
biopsy in the management of gynecologic cancer. ”Curr Opin Obstet
Gynecol,2.411” 27, 66-72, doi:10.1097/gco.0000000000000133 (2015).
32 Cibula D, Abu-Rustum NR, Dusek L, et al. Bilateral ultrastaging of
sentinel lymph node in cervical cancer: lowering the false-negative rate
and improving the detection of micrometastasis. Gynecol Oncol.
2012;127(3):462–466.
33 Slama J, Dundr P, Dusek L, Cibula D. High false negative rate of
frozen section examination of sentinel lymph nodes in patients with
cervical cancer. GYNECOL ONCOL. 2013;129:384-8.
DOI:10.1016/j.ygyno.2013.02.001.
34 Kim JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. The efficacy
of sentinel lymph node mapping with indocyanine green in cervical
cancer. WORLD J SURG ONCOL. 2018;16:52. DOI:10.1186/s12957-018-1341-6.
35 O’Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller
DS. Intraoperative lymphatic mapping in cervix cancer patients
undergoing radical hysterectomy: A pilot study. GYNECOL ONCOL.
2000;79:238-43. DOI:10.1006/gyno.2000.5930.
36 Moncayo VM, Alazraki AL, Alazraki NP, Aarsvold JN. Sentinel Lymph
Node Biopsy Procedures. Semin Nucl Med. 2017;47:595-617.
DOI:https://doi.org/10.1053/j.semnuclmed.2017.06.004.
37 Eiriksson, L. R. & Covens, A. Sentinel lymph node mapping in
cervical cancer: the future? ”Bjog-An International Journal Of
Obstetrics And Gynaecology,5.193” 119, 129-133,
doi:10.1111/j.1471-0528.2011.03134.x (2012).
38 Twu NF, Ou YC, Liao CI, Chang WY, Yang LY, Tang YH, et al. Prognostic
factors and adjuvant therapy on survival in early-stage cervical
adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A
Taiwanese Gynecologic Oncology Group (TGOG) study. SURG ONCOL.
2016;25:229-35. DOI:10.1016/j.suronc.2016.05.028.
39 Colturato, L. F., Signorini Filho, R. C., Fernandes, R. C., et al.
Lymph node micrometastases in initial stage cervical cancer and tumoral
recurrence. Int J Gynaecol Obstet 133, 69-75,
doi:10.1016/j.ijgo.2015.08.019 (2016).
40 Chandacham A, Charoenkwan K, Siriaunkgul S. et al. Extent of
lymphovascular space invasion and risk of pelvic lymph node metastases
in stage IB1 cervical cancer. J Med Assoc Thai 88 Suppl 2, S31-36
(2005).
41 Yanaranop M, Sathapornteera N, Nakrangsee S. Risk factors of pelvic
lymph node metastasis in cervical adenocarcinoma following radical
hysterectomy and pelvic lymphadenectomy. J Med Assoc Thai. 2014;97 Suppl
11: S87-95.
Table 1. Thepatients’ demographic and clinicopathologic informationand analysis of impact
factors on the SLNB detection rate
Categorical variables are presented as absolute frequency (N) and
relative frequency (%), continuous variables are presented as
mean(min-max), comparison between detection rates indicate significance
at P <0.05,
“a”:P-value
of continuous correction chi-square test, SLN: sentinel lymph node,
SLNB: sentinel lymph node biopsy, LVSI: lymphovascular space invasion.